With the research field of targeted hybrid agents still in its infancy, the first clinical application of the PSMA-11-derived peptidomimetic PSMA-targeting hybrid molecule PSMA-914 demonstrated the potential of this technology for the surgical treatment of PCa patients [14]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.